{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:40:01Z","timestamp":1749109201160,"version":"3.41.0"},"reference-count":11,"publisher":"Gobierno de Navarra","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"published-print":{"date-parts":[[2020,8,31]]},"DOI":"10.23938\/assn.0875","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T09:56:10Z","timestamp":1596189370000},"page":"267-271","source":"Crossref","is-referenced-by-count":3,"title":["Unusual evolution of reactive arthritis after endovesical immunotherapy with BCG"],"prefix":"10.23938","volume":"43","member":"10024","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. LAMM DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31: S86-S90. https:\/\/doi.org\/10.1086\/314064","DOI":"10.1086\/314064"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. LAMM DL, VAN DER MEIJDEN ADPM, MORALES A et al. (1992) Incidence and treatment of Bacillus Calmette Guerin intravesical therapy in superficial bladder cancer. J Urol 147; 596-600. https:\/\/doi.org\/10.1016\/s0022-5347(17)37316-0","DOI":"10.1016\/S0022-5347(17)37316-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Tinazzi E, Ficarra V, Simeoni S, Artibani W, Lunardi. C. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006; 26: 481-488. https:\/\/doi.org\/10.1007\/s00296-005-0059-2","DOI":"10.1007\/s00296-005-0059-2"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. MORALES A, NICKEL JG. Immunotherapy of superficial bladder cancer with BCG. World J Urol 1976; 3: 209-214. https:\/\/doi.org\/10.1007\/bf00632180","DOI":"10.1007\/BF00632180"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. GUALLAR-GARRIDO S, JULI\u00c1N E. Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update. Immunotargets Ther 2020; 9: 1-11. https:\/\/doi.org\/10.2147\/itt.s202006","DOI":"10.2147\/ITT.S202006"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. LAMM DL, STODGILL VD, STODGILL BJ, CRISPEN RG. Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135: 272-274. https:\/\/doi.org\/10.1016\/s0022-5347(17)45606-0","DOI":"10.1016\/S0022-5347(17)45606-0"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. RAHEEM OA, KALUNIAN K. KELLOGG PARSONS J. Artritis aguda secundaria a bacilo de Calmette-Gu\u00e9rin intravesical en el c\u00e1ncer de vejiga. Actas Urol Esp 2012; 36: 461-466. https:\/\/doi.org\/10.1016\/j.acuro.2012.02.006","DOI":"10.1016\/j.acuro.2012.02.006"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. PRESCOTT S, JAMES K, BUSUTTIL A, HARGREAVE TB, CHISHOLM GD, SMYTH JF. HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 1989; 63: 264-269. https:\/\/doi.org\/10.1111\/j.1464-410x.1989.tb05187.x","DOI":"10.1111\/j.1464-410X.1989.tb05187.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. RODR\u00cdGUEZ F, PALOU J, R. MART\u00cdNEZ, O. RODR\u00cdGUEZ, A. ROSALES, HUGUET J, VILLAVICENCIO H. Esquema pr\u00e1ctico del manejo de los efectos adversos asociados con la instilaci\u00f3n de BCG. Arch. Esp. Urol 2008; 61: 591-596. https:\/\/doi.org\/10.4321\/s0004-06142008000500004","DOI":"10.4321\/S0004-06142008000500004"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. CARTER JD, HUDSON AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am 2009; 35: 21-44. https:\/\/doi.org\/10.1016\/j.rdc.2009.03.010","DOI":"10.1016\/j.rdc.2009.03.010"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. NGUYEN MH, GIORDANI MM, THOMPSON GR. The double-edged sword - prosthetic joint infection following BCG treatment for bladder cancer: a case report. BMC Infect Dis 2019; 19: 331. https:\/\/doi.org\/10.1186\/s12879-019-3951-1","DOI":"10.1186\/s12879-019-3951-1"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/79380\/61517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:12:47Z","timestamp":1749107567000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/79380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.0875","relation":{},"ISSN":["1137-6627"],"issn-type":[{"type":"print","value":"1137-6627"}],"subject":[],"published":{"date-parts":[[2020,8,31]]}}}